Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2019-03-19 16:08:36
Reporting Period:
Accepted Time:
2019-03-19 16:08:36
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
875045 Biogen Inc. BIIB Biological Products, (No Disgnostic Substances) (2836) 330112644
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1236188 W Robert Pangia Biogen Inc.
225 Binney Street
Cambridge MA 02142
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-03-18 6,114 $52.22 24,701 No 4 M Direct
Common Stock Disposition 2019-03-18 6,114 $328.55 18,587 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2019-03-18 6,114 $0.00 6,114 $53.43
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2010-06-03 2019-06-02 No 4 M Direct
  1. Exercise/sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934.
  2. This option was previously reported as covering 5,975 shares at an exercise price of $53.43 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017.
  3. Granted under one of the Issuer's stock option plans, in an exempt transaction under SEC Rule 16(b)-3(d).